Last Update 16 Jun 26
Fair value Increased 0.34%SBRA: Sector Repricing And Lower Discount Rate Will Support 2026 Upside
The analyst fair value estimate for Sabra Health Care REIT has moved slightly higher to $22.77 from $22.69, as analysts factor in updated price targets across the sector along with modest adjustments to revenue growth, discount rate assumptions, profit margin expectations, and future P/E multiples.
Analyst Commentary
Recent Street research has centered on modestly higher price targets for Sabra Health Care REIT, which helps explain the small upward move in the overall fair value estimate. These updates generally reflect refreshed REIT models rather than any single company specific event.
Bullish Takeaways
- Bullish analysts are lifting price targets into the low to mid US$20s, which signals confidence that the current valuation still leaves some room for execution on the existing portfolio and capital plan.
- The broad review of REIT models, including Sabra, suggests analysts see the sector level assumptions on discount rates, revenue growth, and profit margins as reasonable for supporting current P/E multiples.
- One large bank research desk has set a US$25 target, placing Sabra toward the higher end of recent target ranges and indicating that, in their view, the stock can support a premium versus more cautious targets if management continues to deliver on its plan.
- Updates to targets following Q1 sector work, including commentary on real estate leasing and tenant demand in other property types, point to analysts taking a more constructive stance on REIT cash flow durability generally, which feeds into Sabra’s valuation work.
Bearish Takeaways
- Several targets are clustered around US$22, in line with the updated fair value estimate, which signals that some bearish analysts see limited upside relative to current pricing once execution and sector risks are factored in.
- Neutral and Sector Perform ratings attached to some of the higher targets highlight that, even with raised numbers, analysts still see a balance of risk and reward rather than a clearly compelling opportunity.
- The reference to mixed rent trends and below prior cycle occupancy in parts of the broader real estate universe serves as a reminder that Sabra’s valuation remains tied to sector wide headwinds that could weigh on P/E multiples if conditions soften.
- Incremental US$1 increases in a few targets suggest a cautious, step by step approach to incorporating new information, rather than a strong conviction shift in growth, margins, or discount rate assumptions for the stock.
What’s in the News
- No recent company specific news for Sabra Health Care REIT is available in the provided sources at this time.
- The latest fair value work referenced above reflects analyst model updates rather than any newly reported transaction, financing, or operational announcement.
- Sector level REIT research, rather than discrete Sabra headlines, appears to be the key driver behind recent target and fair value adjustments.
Valuation Changes
- Fair Value: The analyst fair value estimate has risen slightly from $22.69 to $22.77 per share.
- Discount Rate: The discount rate assumption has edged lower from 7.88% to 7.83%, reflecting a modest adjustment in required return.
- Revenue Growth: The long term revenue growth input has moved slightly higher from 14.18% to 14.55%.
- Net Profit Margin: The net profit margin assumption has been trimmed from 20.73% to 20.30%.
- Future P/E: The forward P/E multiple used in the models has shifted modestly higher from 33.17x to 33.61x.
Key Takeaways
- Demand for senior housing outpaces supply, boosting occupancy, rents, and long-term cash flow for Sabra as barriers to new development remain high.
- Strategic acquisitions and limited new competition enhance Sabra's pricing power, margin expansion, and diversified growth across attractive healthcare segments.
- Reliance on new operators, aggressive acquisitions, regulatory risks, and limited reinvestment capacity could undermine asset quality, margins, dividend stability, and future growth.
Catalysts
About Sabra Health Care REIT- Sabra Health Care REIT, Inc. as of March 31, 2025 investment portfolio included 364 real estate properties held for investment (consisting of (i) 224 skilled nursing/transitional care facilities, (ii) 39 senior housing communities (senior housing - leased), (iii) 69 senior housing communities operated by third-party property managers pursuant to property management agreements (senior housing - managed), (iv) 17 behavioral health facilities and (v) 15 specialty hospitals and other facilities), 15 investments in loans receivable (consisting of three mortgage loans and 12 other loans), four preferred equity investments and two investments in unconsolidated joint ventures.
- Persistent and accelerating demand for senior housing, assisted living, and memory care driven by the aging U.S. population-specifically the Baby Boomer cohort-continues to outpace new supply due to high barriers to development; this supports higher occupancy, rising rents, and long-term revenue and cash NOI growth across Sabra's property portfolio.
- The limited new development of senior housing driven by elevated construction and financing costs has created a supply-demand imbalance in key markets, giving Sabra pricing power for rent increases and occupancy gains, resulting in expanding margins and boosting net operating income.
- Substantial reinvestment and $500 million in targeted acquisitions, primarily focused on high-quality, newly built senior housing assets attractive to the current age cohort, are expected to fuel external growth and mix shift toward higher-growth, higher-margin properties-directly benefiting earnings, cash flow, and FFO.
- Stable-to-increasing government reimbursement rates in skilled nursing and strong private investment in healthcare infrastructure, combined with Sabra's proactive operator selection and portfolio management, underpin improved rent coverage, reduce income volatility, and underpin future net margin and dividend security.
- Ongoing shift toward value-based and out-of-hospital care settings (assisted living, post-acute, behavioral health) increases long-term need for real estate solutions provided by Sabra, reinforcing multi-year growth in rental income, cash NOI, and AFFO.
Sabra Health Care REIT Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Sabra Health Care REIT's revenue will grow by 14.5% annually over the next 3 years.
- Analysts assume that profit margins will increase from 19.1% today to 20.3% in 3 years time.
- Analysts expect earnings to reach $248.9 million (and earnings per share of $0.81) by about June 2029, up from $156.2 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 33.6x on those 2029 earnings, up from 30.0x today. This future PE is lower than the current PE for the US Health Care REITs industry at 38.0x.
- Analysts expect the number of shares outstanding to grow by 5.17% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.83%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The portfolio shakeup involving transition of Holiday assets to new operators introduces execution risk; if new operators underperform or the transition is not smooth, occupancy and NOI could suffer, impacting both revenue growth and margin expansion.
- Despite positive near-term demand/supply dynamics, the outlook assumes continued tight supply; if interest rates decline or capital costs ease, new construction could eventually come online and increase competition, leading to lower rental growth and increased vacancy risk, weighing on future revenues.
- The company's pipeline relies heavily on senior housing assets (SHOP) and entails a significant ramp-up in acquisitions; overly aggressive expansion while depending on newer or unproven operators or imperfect asset selection risks diluting asset quality and compressing net margins.
- Regulatory and government reimbursement risk remains; while management downplayed immediate concern, Medicaid and Medicare rates are subject to political and fiscal pressures, and future cuts or slower increases could strain operator coverage ratios and Sabra's rent collection reliability, threatening both revenue and FFO.
- A high payout ratio (dividend at 79% of AFFO) means limited retained cash for reinvestment or deleveraging; if operating or investment performance falters, or if tenant financial health deteriorates, Sabra may be forced to trim its dividend, negatively impacting earnings and share price sentiment.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $22.77 for Sabra Health Care REIT based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $25.0, and the most bearish reporting a price target of just $20.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $248.9 million, and it would be trading on a PE ratio of 33.6x, assuming you use a discount rate of 7.8%.
- Given the current share price of $18.58, the analyst price target of $22.77 is 18.4% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Sabra Health Care REIT?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.